Axsome Therapeutics Inc (AXSM)
99.56
-0.92
(-0.92%)
USD |
NASDAQ |
Dec 04, 16:00
99.40
-0.16
(-0.17%)
After-Hours: 20:00
Axsome Therapeutics Enterprise Value: 4.723B for Dec. 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| December 03, 2024 | 4.723B |
| December 02, 2024 | 4.654B |
| November 29, 2024 | 4.613B |
| November 27, 2024 | 4.682B |
| November 26, 2024 | 4.555B |
| November 25, 2024 | 4.578B |
| November 22, 2024 | 4.635B |
| November 21, 2024 | 4.611B |
| November 20, 2024 | 4.437B |
| November 19, 2024 | 4.479B |
| November 18, 2024 | 4.333B |
| November 15, 2024 | 4.368B |
| November 14, 2024 | 4.571B |
| November 13, 2024 | 4.594B |
| November 12, 2024 | 4.674B |
| November 11, 2024 | 4.262B |
| November 08, 2024 | 4.218B |
| November 07, 2024 | 4.248B |
| November 06, 2024 | 4.261B |
| November 05, 2024 | 4.177B |
| November 04, 2024 | 4.079B |
| November 01, 2024 | 4.156B |
| October 31, 2024 | 4.165B |
| October 30, 2024 | 4.186B |
| October 29, 2024 | 4.229B |
| Date | Value |
|---|---|
| October 28, 2024 | 4.217B |
| October 25, 2024 | 4.206B |
| October 24, 2024 | 4.155B |
| October 23, 2024 | 4.324B |
| October 22, 2024 | 4.328B |
| October 21, 2024 | 4.285B |
| October 18, 2024 | 4.374B |
| October 17, 2024 | 4.374B |
| October 16, 2024 | 4.210B |
| October 15, 2024 | 4.039B |
| October 14, 2024 | 3.990B |
| October 11, 2024 | 4.094B |
| October 10, 2024 | 3.877B |
| October 09, 2024 | 3.899B |
| October 08, 2024 | 3.961B |
| October 07, 2024 | 3.929B |
| October 04, 2024 | 4.047B |
| October 03, 2024 | 4.269B |
| October 02, 2024 | 4.369B |
| October 01, 2024 | 4.237B |
| September 30, 2024 | 4.206B |
| September 27, 2024 | 4.166B |
| September 26, 2024 | 4.166B |
| September 25, 2024 | 4.180B |
| September 24, 2024 | 4.247B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
657.91M
Minimum
Aug 19 2021
4.723B
Maximum
Dec 03 2024
2.611B
Average
2.691B
Median
Enterprise Value Benchmarks
| Repligen Corp | 8.058B |
| Pfizer Inc | 201.79B |
| NovaBay Pharmaceuticals Inc | 2.076M |
| Palatin Technologies Inc | 18.73M |
| iBio Inc | 13.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -64.60M |
| Revenue (Quarterly) | 104.76M |
| Total Expenses (Quarterly) | 151.00M |
| EPS Diluted (Quarterly) | -1.34 |
| Gross Profit Margin (Quarterly) | 91.95% |
| Profit Margin (Quarterly) | -61.67% |
| Earnings Yield | -6.56% |
| Normalized Earnings Yield | -5.287 |